291 related articles for article (PubMed ID: 11436381)
1. Prescription for conflict. AMA accepts funding from drug firms for campaign.
Romano M
Mod Healthc; 2001 Jun; 31(25):14. PubMed ID: 11436381
[No Abstract] [Full Text] [Related]
2. AMA forges ahead. Unveiling of educational campaign paid by drug industry triggers new criticism.
Romano M
Mod Healthc; 2001 Sep; 31(37):22-3. PubMed ID: 11573355
[No Abstract] [Full Text] [Related]
3. Two views on funding. Drug firm's financial support of AMA ethics campaign poses a debate.
Romano M
Mod Healthc; 2001 Apr; 31(17):12. PubMed ID: 11338891
[No Abstract] [Full Text] [Related]
4. Future directions in industry funding of continuing medical education.
Steinbrook R
Arch Intern Med; 2011 Feb; 171(3):257-8. PubMed ID: 21325116
[No Abstract] [Full Text] [Related]
5. Continuing medical education: ethical collaboration between sponsor and industry.
Wilson FS
Clin Orthop Relat Res; 2003 Jul; (412):33-7. PubMed ID: 12838049
[TBL] [Abstract][Full Text] [Related]
6. Too friendly? Teaching hospitals revisit ties to pharmaceutical firms.
Romano M
Mod Healthc; 2003 Jul; 33(28):17. PubMed ID: 12884711
[No Abstract] [Full Text] [Related]
7. Deep in the data mine. AMA sales of doc info lead to partnership questions.
Conn J
Mod Healthc; 2007 Jun; 37(23):8-9. PubMed ID: 17612000
[No Abstract] [Full Text] [Related]
8. Industry support and professional medical associations.
Smith CD; Buyske J; Talamini MA
JAMA; 2009 Aug; 302(7):738-9; author reply 739. PubMed ID: 19690303
[No Abstract] [Full Text] [Related]
9. When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Hensley S
Wall St J (East Ed); 2002 Dec; ():A1, A12. PubMed ID: 12653117
[No Abstract] [Full Text] [Related]
10. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey.
Rutledge P; Crookes D; McKinstry B; Maxwell SR
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):663-7. PubMed ID: 14762982
[TBL] [Abstract][Full Text] [Related]
11. Current guidelines regarding industry-sponsored continuing medical education.
DelSignore JL
Clin Orthop Relat Res; 2003 Jul; (412):21-7. PubMed ID: 12838047
[TBL] [Abstract][Full Text] [Related]
12. Issues of conflict resolution. Critics ask why council backed off tighter restrictions.
Rhea S
Mod Healthc; 2009 Aug; 39(31):8-9. PubMed ID: 19688888
[No Abstract] [Full Text] [Related]
13. Student rally. Med school attendees write ethics code on drug firms.
Romano M
Mod Healthc; 2002 May; 32(19):24, 26. PubMed ID: 12038157
[No Abstract] [Full Text] [Related]
14. The Glaxo Award: is the American Public Health Association moving toward corporate governance?
David R
Int J Health Serv; 2002; 32(1):205-7. PubMed ID: 11913858
[No Abstract] [Full Text] [Related]
15. Conflicts of interest, conflicting interests, and interesting conflicts, Part 3.
Orlowski JP; Vinicky JK; Edwards SS
J Clin Ethics; 1996; 7(2):184-6. PubMed ID: 8889894
[No Abstract] [Full Text] [Related]
16. [Drug industry and bribes].
Annertz M
Lakartidningen; 2004 Apr; 101(15-16):1436. PubMed ID: 15146680
[No Abstract] [Full Text] [Related]
17. AMA seeks full conflict disclosure.
Romano M
Mod Healthc; 2001 Sep; 31(37):6. PubMed ID: 11605600
[No Abstract] [Full Text] [Related]
18. Continuing medical education and pharmaceutical industry.
Vakani FS; Jafri W; Amin A; Sheerani M
J Coll Physicians Surg Pak; 2011 Jun; 21(6):360-1. PubMed ID: 21711993
[TBL] [Abstract][Full Text] [Related]
19. CMA guidelines on MD-drug industry relations part of international trend.
Williams JR
CMAJ; 1992 Feb; 146(3):386-8. PubMed ID: 11654902
[No Abstract] [Full Text] [Related]
20. AMPAC campaign contributions to congress--a correction.
Sharfstein J; Sharfstein S
N Engl J Med; 1995 May; 332(21):1450. PubMed ID: 7723814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
